{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0"},{"groupId":"OG001","value":"65.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"description":"The percentage of participants with at least one submission to healthcare encounter was assessed.","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"Safety Set. Six participants in the BAT arm discontinued before receiving the first dose.","reportingStatus":"POSTED","timeFrame":"from Baseline to LPLV (approximately 5 years)","title":"Utilization of Medical Resources","type":"SECONDARY","unitOfMeasure":"percentage of participants"}